Tests several cancer drugs in children and young adults
Tests several cancer drugs in children and young adults with cancer.
Plain-language title generated from the registry record
Registry title: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Key facts
- Where
- Leiden and Utrecht, NetherlandsSee the 2 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 39 years old?
Source: NCT05999994, who can take part
Where in Netherlands
- Leids Universitair Medisch CentrumLeiden, NetherlandsTaking people
- Prinses Máxima CentrumUtrecht, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT05999994
- Record updated
- 7 August 2026
- Original description
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.Read full original descriptionShow less
CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Inclusion: Participants must meet all of the inclusion criteria below. Additional criteria are specified in the protocol amendment (individual addenda) to which the participant will enroll; Have either measurable or evaluable disease using standard techniques by the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1); The participant has a Lansky (<16 years of age) or Karnofsky (≥16 years of age) performance score of at least 50; Participants must have discontinued all previous treatments for cancer or investigational agents greater than or equal to (≥)7 days after the last dose and must have recovered from clinically significant side effects; The participant has adequate hematologic and organ function; Female participants of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to first dose; Both female and male participants of childbearing potential must agree to use highly effective contraceptive precautions during the trial and for at least 3 months following the last dose of study drug; Participants will be ineligible if they meet any of the exclusion criteria below. Additional criteria are specified in the protocol amendment to which the participant will enroll; Participants with severe and/or uncontrolled concurrent medical disease or psychiatric illness/social situation that, in the opinion of the investigator, could cause unacceptable safety risks or compromise compliance with the protocol; Participants who have active infections requiring therapy; Participants who have had allogeneic bone marrow or solid organ transplant; Participants who have had, or are planning to have, certain invasive procedures; Female participants who are pregnant or breastfeeding.